The Covid-19 virus often finds many that have fibrosis of the lungs. It impacts patients even after recovery, reducing lung function.
Cannabidiol (CBD) is known to exert immunomodulatory effects through the activation of cannabinoid-1 and – 2 (CB1 and CB2) receptors located in the central nervous system and immune cells, respectively. The role of CBD on airway remodelling and the mechanisms of CB1 and CB2 aren’t fully elucidated, studies have been done to evaluate the effects of cannabidiol with airway inflammation.
Asthma is characterized by chronic lung inflammation and airway hyperresponsiveness. Asthma remains a major public health problem and, at present, there are no effective interventions capable of reversing airway remodelling. CBD treatment, regardless of dosage, decreased airway hyperresponsiveness, whereas static lung elastance only reduced with high dose. These outcomes were accompanied by decreases in collagen fibre content in both airway and alveolar septa and the expression of markers associated with inflammation in the bronchoalveolar lavage fluid and lung homogenate. CBD treatment decreased the inflammatory and remodelling processes in the model of allergic asthma.
Find out more at the Richard Rose Report